Literature DB >> 22736319

Acute liver failure secondary to gemcitabine.

Alice Stellman1, Mei Mei Loke, Steven Mann.   

Abstract

Gemcitabine is widely used in oncology practice. There are rare reports of gemcitabine causing hepatotoxicity with all affected patients dying from acute liver failure. We describe a patient with stage 4 lymphoma who presented with an acute deterioration in liver function tests and hepatic encephalopathy not directly attributed to his disease. He had been taking gemcitabine for 5 months before admission. His clinical and biochemical problems resolved after discontinuing the drug. This is the first case described of a severe hepatotoxic reaction associated with gemcitabine that was followed by a complete recovery.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 22736319      PMCID: PMC3047552          DOI: 10.1136/bcr.12.2008.1371

Source DB:  PubMed          Journal:  BMJ Case Rep        ISSN: 1757-790X


  5 in total

1.  A fatal case of cholestatic liver failure probably related to gemcitabine.

Authors:  D C Coeman; E K Verbeken; K L Nackaerts; M G Demedts; J F Vansteenkiste
Journal:  Ann Oncol       Date:  2000-11       Impact factor: 32.976

2.  Fatal hepatic failure due to gemcitabine and vinorelbine.

Authors:  K Kagohashi; Y Funayama; H Satoh; K Sekizawa
Journal:  Ann Oncol       Date:  2003-06       Impact factor: 32.976

3.  Veno-occlusive disease of the liver induced by gemcitabine.

Authors:  M Dobbie; S Hofer; M Oberholzer; R Herrmann
Journal:  Ann Oncol       Date:  1998-06       Impact factor: 32.976

Review 4.  Gemcitabine--a safety review.

Authors:  M S Aapro; C Martin; S Hatty
Journal:  Anticancer Drugs       Date:  1998-03       Impact factor: 2.248

5.  Fatal cholestatic liver failure associated with gemcitabine therapy.

Authors:  Keith Robinson; Louis Lambiase; Jianjun Li; Carmela Monteiro; Michael Schiff
Journal:  Dig Dis Sci       Date:  2003-09       Impact factor: 3.199

  5 in total
  1 in total

1.  Idiopathic hyperammonemic encephalopathy secondary to gemcitabine-cisplatin treatment.

Authors:  Karlijn Verkerk; Hans-Martin Otten; Alwin D R Huitema
Journal:  Cancer Chemother Pharmacol       Date:  2022-09-20       Impact factor: 3.288

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.